Home / Themes / MedTech Long '24: Trump-Favorable Regs
MedTech Long '24: Trump-Favorable Regs (view performance)
Last updated
Theme thesis · 3/5 sections · Tickers 1 with notes · 7 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsThe MedTech '24 Trump-Favorable Regs subtheme is built on the belief that the Trump 2.0 administration's deregulatory and innovation-forward healthcare agenda—p
Thesis
The MedTech '24 Trump-Favorable Regs subtheme is built on the belief that the Trump 2.0 administration's deregulatory and innovation-forward healthcare agenda—particularly under HHS nominee RFK Jr.—will accelerate device approval, simplify reimbursement, and improve operating conditions for smaller, domestically focused, innovative medtech companies. This policy shift is seen as a rerun of the Trump 1.0 cycle which led to record medtech outperformance.
Bull case
Regulatory Tailwinds: Trump's policies are expected to reimplement fast-tracking for breakthrough devices and reduce FDA oversight for many diagnostics. RFK-backed HHS leadership is deregulatory and pro-access for alternative and tech-driven treatments
Reimbursement Upside: Recent CMS decisions under Trump increased Medicare Advantage rates more than expected, a boon to coverage for MedTech procedures and diagnostics, supporting utilization and revenues across the board
GLP-1 Narrative Reversal: Former shorts like DXCM and EXAS are now viewed as potentially over-penalized, with tailwinds emerging from improved patient access and new indications (e.g., CVRX and NARI benefitting from weight-loss-related surgical eligibility)
Bear case
PBM and CMS Budget Reforms Could Bite: While deregulation helps medtech, broader budget-tightening measures—especially scrutiny on CMS reimbursement and discretionary payments—could hit device makers reliant on public health dollars
Interest Rate Volatility Resurgence: Medtech has historically been viewed as highly rate-sensitive. If inflation or deficit pressures push rates higher again, duration-heavy medtech names like DXCM or HQY could suffer multiple compression
RFK Policy Risk and Recession Exposure: RFK's non-mainstream views (e.g., anti-vax leanings, preference for alternative medicine) may alienate mainstream medical stakeholders and complicate implementation of positive reforms. Simultaneously, if recession hits, elective procedures and diagnostics may see volume contraction.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| Utilization Trends in Cardio, Diabetes, Diagnostics | Quarterly | Real-world procedure volume trends and patient access — directly drives revenue (DXCM, NARI, EXAS, CVRX). | Google_Sheets |
| CMS Reimbursement Rate Updates (MA & Devices) | Quarterly | Direct revenue and margin impact via reimbursement rates for diagnostics and devices (EXAS, CVRX, MDWD). | Google_Sheets |
| FDA 510(k) & Breakthrough Device Approval Volume | Monthly | Tracks pace of regulatory approvals; confirms deregulatory tailwinds (DXCM, NARI, MDWD). | Google_Sheets |
Upcoming Catalysts
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| DXCM_e0606eaf | before the end of this year | 2026-08-07 | 2026-12-31 | CMS decision on coverage expansion for Type 2 non-insulin diabetes patients, following the submission of Connect trial data. | This decision has the potential to significantly expand the addressable market for Dexcom CGM in the US, impacting 25 million Type 2 non-insulin customers. | Ticker | 2026-07-30 | earnings_transcript | DXCM (ticker) |
| DXCM_b887655c | by year end | 2026-10-01 | 2026-12-31 | Dexcom expects to convert nearly 50% of its US customer base to the G7 15-day system. | This conversion is translating into stronger customer satisfaction and is expected to contribute to improved gross margins. | Ticker | 2026-07-30 | earnings_transcript | DXCM (ticker) |
| DXCM_80554779 | Final rule publication in November 2026; effective January 1, 2027. | 2026-11-01 | 2027-01-01 | CMS to publish the CY 2027 Physician Fee Schedule final rule, finalizing changes to remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) reimbursement policies. | This rule could significantly alter the operational and financial models for companies providing remote monitoring solutions, directly impacting the reimbursement landscape for wearable health devices including Dexcom's offerings. | Theme | 2026-07-30 | earnings_transcript | DXCM (ticker) |
Constituents
- DXCMT2— DexCom, Inc.
- EXAST2· no notes yet
- CVRXT3· no notes yet
- HQYT3· no notes yet
- IBO.VT3· no notes yet
- MDWDT3· no notes yet
- NARIT3· no notes yet
- PBMT3· no notes yet